Update on Pfizer’s Duchenne gene therapy Phase 3 clinical program In line with our continued efforts to work with the Duchenne community and share information as it becomes available, we […]
Results suggest a highly potent next-generation treatment that could offer greater efficacy with less frequent dosing SRP-5051 dosed monthly at 30 mg/kg delivered mean exon skipping of 10.79% and mean dystrophin […]
Today, CureDuchenne Ventures is pleased to share that we made a research investment into Code BioTherapeutics and their next-generation gene therapy platform. This is a promising technology aimed at overcoming […]
CureDuchenne continued funding a robust Duchenne drug development pipeline with a new investment in Entrada Therapeutics as part of their latest financing from a group of investors. Entrada Therapeutics’ promising […]
March 15, 2021 CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), […]
EDO platform demonstrates potentially best-in-class safety and efficacy profile in addressing DMD and DM1 disease phenotypes Advancing rapidly to the clinic with first-in-human studies expected to initiate in early 2022 […]
Pratteln, Switzerland, March 3, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces that the last patient has completed the last visit for the first period of the placebo-controlled pivotal VISION-DMD study with […]
************** Join CureDuchenne and Sarepta on March 4 for a webinar discussing the below announcement. CureDuchenne Webinar: Sarepta Therapeutics update on RNA Exon-Skipping program and Patient Support Services In this […]
Dear Duchenne Community, All of us at Italfarmaco would like to thank the families participating in the Phase 3 EPIDYS trial and in the open label extension study of givinostat […]
